The US National Cancer Institute is launching an 'exceptional responder' programme to see whether outliers from failed cancer trials can open up new drug development avenues.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma
Blood Cancer Journal Open Access 30 June 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. Learning from exceptional drug responders. Nat Rev Drug Discov 13, 401–402 (2014). https://doi.org/10.1038/nrd4338
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4338
This article is cited by
-
A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma
Blood Cancer Journal (2017)
-
Exceptional responders—discovering predictive biomarkers
Nature Reviews Clinical Oncology (2015)